Simultaneous determination of NK611, a novel water-soluble derivative of etoposide, and its metabolite (DeNK611) in dog plasma by column-switching high performance liquid chromatography.
A simple, selective, reversed phase liquid chromatographic method using a column-switching technique has been developed for the simultaneous determination of a novel derivative of etoposide (NK611) and its O-demethyl metabolite in dog plasma. A good linear response was obtained for both drugs in the range 0.1-12.0 micrograms/mL. The mean recoveries were within 100 +/- 5%. The within- and between-day precisions were within 3.5% and 4.6%, respectively. This method was used in a pharmacokinetic study following intravenous and oral administration of NK611 to beagle dogs.
Machida
M
M
Takasaki Research Laboratories, Nippon Kayaku Co. Ltd., Gunma, Japan.
Tanaka
S
S
Nakamori
K
K
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004285:Dogs; D005047:Etoposide / Q000031:analogs & derivatives*; D007262:Infusions, Intravenous; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; C080080:NK 611; C081076:DeNK 611; D005047:Etoposide; D011034:Podophyllotoxin